SanFran,

I completely agree with you that a formal Zenith corporate update is warranted.

Zenith Capital Corp/Zenith Epigenetic Ltd Arrangement: Way back in the December 2, 2015 management information circular is when we first heard about the proposed Zenith Capital Corp/Zenith Epigenetics Ltd arrangement that was anticipated to close February 1, 2016. Sarah has communicated to us that Zenith decided to delay the closing of the deal until after the start of the prostate cancer trial. Well......we are past that now. What is the latest update on this arrangement? Still in the works? Plan changed?

Licensing deal(s): What about the progress on the China (and other countries) licensing deal(s) that Don referred to at the January 7, 2016 Annual Meeting?

Animal Health/Orphan Indications? What about the progress on the expansion to other indications, specifically animal health and other orphan indications as referred to at the January 2016 Annual Meeting and the January 2016 Biotech Showcase slides?

Reverse Takeover: What is the latest company developments on the idea of performing a reverse takeover of another company to get an IPO onto the Nasdaq that was mentioned at the January 2016 Annual Meeting? I imagine that the Arrangement would need to close first since they only plan to IPO the Zenith Epigenetics Ltd portion.

The only events on the Zenith schedule to close out Q2 2016 are the June 3, 2016 ASCO meeting (attending but not presenting per Sarah) and the June 6, 2016 BIO International Convention. However, Sarah indicated to me via email that there will be no Zenith presentation at the BIO International Convention.

Asking for an update is completely reasonable.

BearDownAZ